FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific antibody or a fragment of this bispecific antibody that binds to the transferrin receptor (TfR) and to a cell surface antigen, as well as to a method of its preparation. Also the following is disclosed: the DNA encoding the above antibody or a fragment thereof, as well as the vector and transformant containing it.
EFFECT: invention is effective for treating a disease associated with at least one of human TfR and EGFR, which is a cancer.
18 cl, 21 dwg, 7 tbl, 20 ex
Title | Year | Author | Number |
---|---|---|---|
BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
METHOD OF PRODUCING A POLYPEPTIDE HETEROMULTITERS | 2014 |
|
RU2730594C2 |
METHOD FOR PRODUCING A POLYPEPTIDE HETEROMULTIMER | 2014 |
|
RU2758952C1 |
BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
BISPECIFIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2787783C2 |
BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
Authors
Dates
2023-12-28—Published
2019-12-27—Filed